TLDR: Melbourne-based healthtech innovator Everlab has successfully closed a US$10 million (AU$15 million) seed funding round, spearheaded by global growth equity firm Left Lane Capital. This significant investment is earmarked to accelerate the global expansion of Everlab’s AI-driven preventive healthcare platform, which aims to provide personalized interventions to combat chronic diseases.
Melbourne, Australia – July 22, 2025 – Everlab, a pioneering health technology startup dedicated to transforming preventive healthcare, today announced it has secured US$10 million (approximately AU$15 million) in seed funding. The round was led by New York and London-based global growth equity firm Left Lane Capital, with additional support from existing investor AfterWork Ventures. This substantial capital injection is set to propel Everlab’s mission to scale its AI-powered platform internationally and enhance its proprietary health technology.
Everlab operates at the forefront of preventive healthcare, addressing the critical global challenge posed by chronic diseases, which are responsible for over 70% of deaths worldwide. In contrast to traditional reactive healthcare models that treat conditions post-symptom, Everlab champions a proactive approach, delivering personalized health interventions at scale. The company leverages artificial intelligence to generate personalized diagnostics, health alerts, and tailored lifestyle plans, all based on continuous biomarker data.
Marc Hermann, Founder and CEO of Everlab, emphasized the company’s vision, stating, “We believe everyone deserves access to world-class preventive care. By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions.”
The newly acquired funds will be strategically allocated towards several key areas: international expansion, further development and enhancement of its AI healthtech platform, and the growth of its integrated ecosystem of products and clinical teams. While specific valuation details remain undisclosed, the backing from Left Lane Capital, known for its investments in high-growth tech companies, underscores strong investor confidence in Everlab’s innovative model.
Also Read:
- LeadStory Secures $2.75 Million Seed Funding to Propel AI-Powered News Platform
- Metly Raises €520K Pre-Seed to Revolutionize Pharma Business Development with AI
Everlab’s platform aims to bring predictive care into everyday health management, offering a scalable solution to a pressing global health crisis. The company’s focus on early intervention and personalized care, augmented by advanced AI capabilities, positions it as a significant player in the evolving healthtech landscape.
